Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
ARQT Stock — Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT)
Updated October 16, 2026.
ARQT is a Stock. Total return is 32.2% over the past 6.7 years, 128.7 points behind SPY at 160.9%.
Arcutis Biotherapeutics is a biopharmaceutical company developing and commercializing treatments for dermatological diseases, with its lead product ZORYVE, a topical roflumilast cream approved for plaque psoriasis and atopic dermatitis, along with additional formulations and pipeline candidates in development. The company does not currently distribute income to shareholders. This stock may appeal to investors seeking exposure to clinical-stage and commercial-stage dermatology therapeutics rather than current income.
ARQT performance versus SPY
Price and return data through 2026-10-16.
Total return is 32.2% over the past 6.7 years, 128.7 points behind SPY at 160.9%. Over the past year its total return — price change plus distributions reinvested — is 37.8%. Its deepest 1-year drawdown was 37.5%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | 10.3% | — |
| 3M | 3.9% | — |
| 6M | 19.1% | — |
| YTD | -0.8% | — |
| 1Y | 37.8% | — |
| 2Y CAGR | — | 72.30% |
| 3Y CAGR | — | 97.20% |
| 5Y CAGR | — | 5.30% |
| Since inception (6.7 years) | 32.2% | 4.30% |
ARQT key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 01/31/2020
- Distribution frequency
- None
- Last close
- $28.82 (as of 2026-10-16)
- Market cap
- $3,622,442,316
- Average volume
- 1731947.0
- Beta
- 1.58
- Payout ratio
- 0.0%
- P/E ratio
- 131.0
- Forward P/E
- 26.3852
- EPS
- $0.22
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
ARQT risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 37.5%.
Who may consider ARQT — and who may not
It is a weaker fit for investors who need monthly cash flow (ARQT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on ARQT
Frequently asked questions
Does ARQT pay monthly?
No. ARQT does not currently distribute.
When does ARQT pay a dividend?
ARQT does not currently distribute.
How has ARQT performed?
Total return is 32.2% over the past 6.7 years, 128.7 points behind SPY at 160.9%. Over the past year its total return — price change plus distributions reinvested — is 37.8%. Its deepest 1-year drawdown was 37.5%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.